No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Achieve Life Sciences Appoints Mark Oki CFO
Express News | Aytu Biopharma Inc - Settlement Hearing Scheduled for January 13, 2025
Aytu BioPharma Disclosure Notification
Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)
US Manufacturing Index Rises To 43, Highest Since 2020
Maxim Group Maintains Aytu BioPharma(AYTU.US) With Buy Rating, Maintains Target Price $8
No Data